(0.08%) 5 252.77 points
(-0.07%) 39 733 points
(0.04%) 16 405 points
(1.22%) $82.34
(1.46%) $1.743
(1.65%) $2 226.70
(0.12%) $24.78
(1.21%) $920.70
(0.23%) $0.925
(0.57%) $10.83
(0.00%) $0.791
(0.08%) $92.52
Live Chart Being Loaded With Signals
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases...
Stats | |
---|---|
Today's Volume | 1 859.00 |
Average Volume | 2 230.00 |
Market Cap | 103.31B |
EPS | €0 ( 2024-02-02 ) |
Next earnings date | ( €0 ) 2024-04-25 |
Last Dividend | €0.570 ( 2023-07-06 ) |
Next Dividend | €0 ( N/A ) |
P/E | 14.13 |
ATR14 | €0.153 (0.31%) |
Bristol-Myers Squibb Co Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Bristol-Myers Squibb Co Financials
Annual | 2023 |
Revenue: | €45.01B |
Gross Profit: | €34.31B (76.24 %) |
EPS: | €0 |
Q4 | 2023 |
Revenue: | €11.48B |
Gross Profit: | €8.73B (76.08 %) |
EPS: | €0 |
Q3 | 2023 |
Revenue: | €10.97B |
Gross Profit: | €8.46B (77.15 %) |
EPS: | €0.940 |
Q2 | 2023 |
Revenue: | €11.23B |
Gross Profit: | €8.35B (74.38 %) |
EPS: | €0.990 |
Financial Reports:
No articles found.
Bristol-Myers Squibb Co Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0.540 (N/A) |
€0.570 (N/A) |
€0.570 (N/A) |
€0.570 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.215 | 1999-06-30 |
Last Dividend | €0.570 | 2023-07-06 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 97 | -- |
Total Paid Out | €33.94 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.93 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.69 | |
Div. Directional Score | 8.19 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TNE5.DE | Ex Dividend Junior | 2023-12-12 | Semi-Annually | 0 | 0.00% | |
ETG.DE | Ex Dividend Knight | 2023-07-04 | Annually | 0 | 0.00% | |
NGLB.DE | Ex Dividend Knight | 2023-08-17 | Semi-Annually | 0 | 0.00% | |
AXA.DE | Ex Dividend Junior | 2023-05-08 | Sporadic | 0 | 0.00% | |
WAF.DE | Ex Dividend Junior | 2023-05-08 | Annually | 0 | 0.00% | |
GZF.DE | Ex Dividend Junior | 2023-04-28 | Annually | 0 | 0.00% | |
PND.F | Ex Dividend Knight | 2023-09-01 | Quarterly | 0 | 0.00% | |
CBHD.DE | Ex Dividend Knight | 2023-05-15 | Semi-Annually | 0 | 0.00% | |
IE2A.F | Ex Dividend Junior | 2023-05-02 | Sporadic | 0 | 0.00% | |
02M.DE | Ex Dividend Knight | 2023-09-06 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.178 | 1.500 | 6.43 | 9.65 | [0 - 0.5] |
returnOnAssetsTTM | 0.0843 | 1.200 | 7.19 | 8.63 | [0 - 0.3] |
returnOnEquityTTM | 0.263 | 1.500 | 8.19 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.591 | -1.000 | 4.09 | -4.09 | [0 - 1] |
currentRatioTTM | 1.427 | 0.800 | 7.86 | 6.29 | [1 - 3] |
quickRatioTTM | 1.237 | 0.800 | 7.43 | 5.94 | [0.8 - 2.5] |
cashRatioTTM | 0.515 | 1.500 | 8.25 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.436 | -1.500 | 2.74 | -4.11 | [0 - 0.6] |
interestCoverageTTM | 8.08 | 1.000 | 8.12 | 8.12 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.62 | 2.00 | 7.79 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 6.04 | 2.00 | 6.98 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.409 | -1.500 | 4.36 | -6.55 | [0 - 2.5] |
grossProfitMarginTTM | 0.762 | 1.000 | 0.627 | 0.627 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.209 | 1.000 | 7.82 | 7.82 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.334 | 1.000 | 9.25 | 9.25 | [0.2 - 2] |
assetTurnoverTTM | 0.473 | 0.800 | -0.180 | -0.144 | [0.5 - 2] |
Total Score | 10.69 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.83 | 1.000 | 8.70 | 0 | [1 - 100] |
returnOnEquityTTM | 0.263 | 2.50 | 8.84 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 6.04 | 2.00 | 7.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.15 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.62 | 2.00 | 7.79 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.591 | 1.500 | 4.09 | -4.09 | [0 - 1] |
pegRatioTTM | 0.231 | 1.500 | -1.794 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.308 | 1.000 | 4.80 | 0 | [0.1 - 0.5] |
Total Score | 5.69 |
Bristol-Myers Squibb Co
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators